恶性黑色素瘤治疗新进展

摘要: 黑色素瘤死亡率高、预后差，近年来随着新型免疫治疗的发展，黑色素瘤成为研究热点，治疗也进入了崭新的阶段。2018年6月1日，美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）年会在芝加哥拉开帷幕，这场学术盛会展示了黑色素瘤领域最前沿的研究，覆盖了淋巴结清扫、辅助治疗、免疫治疗、靶向治疗多个方面，涉及PD-1单抗、恩可非尼（encorafenib）、比尼替尼（binimetinib）等多种药物。本文就上述内容展开讨论，分析其利弊、前景，以期指导中国黑色素瘤的诊治。
- 黑色素瘤 /
- ASCO /
- 治疗
Abstract: Melanoma is characterized by high mortality and poor prognosis. The novel immunotherapy has offered a breakthrough in antitumor activity in melanoma and has offered incremental improvements over standard care. The ASCO annual meeting held on June 1, 2018 in Chicago, was conducted to present the progress of current treatment and promise of those still in clinical development. The academic event showed results of clinical trials in patients with lymph node dissection, adjuvant therapy, immunotherapy, and targeted therapy. Melanoma drugs introduced at the meeting included NIVO, Pembro, T-VEC, Encorafenib, Binimetinib, and CDk4/6i. The development of therapy is retrospected in this paper in order to provide a basis and give hope for melanoma treantment in China.
- melanoma /
- ASCO /
- treantment

HTML全文

参考文献(26)

[1]	Guo J, Qin S, Liang J, et al. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)[J]. Chin Clin Oncol, 2016, 5 (4): 57. doi: 10.21037/cco
[2]	Ploeg AP, Akkooi AC, Rutkowski P, et al. Prognosis in Patients With Sentinel Node Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria[J]. J Clin Oncol, 2011, 29(16):2206-2214. doi: 10.1200/JCO.2010.31.6760
[3]	Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma[J]. N Engl J Med, 2014, 370(7):599-609. doi: 10.1056/NEJMoa1310460
[4]	Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma[J]. N Engl J Med 2017, 376(23):2211-2222. doi: 10.1056/NEJMoa1613210
[5]	Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissec -tion versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, rando-mised, phase 3 trial.[J].Lancet Oncol, 2016, 17(6):757-767. doi: 10.1016/S1470-2045(16)00141-8
[6]	Chi Z, Si L, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic chinese:A study of 522 consecutive cases[J]. BMC Cancer, 2011, 11(1):85. doi: 10.1186/1471-2407-11-85
[7]	Lv J, Dai B, Kong Y, et al. Acral melanoma in chinese: a clinical pathological and prognostic study of 142 casea[J]. Sci Rep, 2016, 6(1): 31432. doi: 10.1038/srep31432
[8]	Weber J, Mandala M, Del VM, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage Ⅲ or IV Melanoma[J]. N Engl J Med, 2017, 377(19):1824-1835. doi: 10.1056/NEJMoa1709030
[9]	Alexander ME, Vanna CS, Jean JG, et al. Adjuvant ipilimumab ver- sus placebo after complete resection of high-risk stage Ⅲ melano- ma (EORTC 18071): a randomised, double- blind, phase 3 trial[J]. Lancet Oncol, 2015, 16:522-530. doi: 10.1016/S1470-2045(15)70122-1
[10]	Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage Ⅲ BRAF- Mutated Melanoma[J]. N Engl J Med, 2017, 377:1813-1823. doi: 10.1056/NEJMoa1708539
[11]	Thompson JF. Local and regional therapies for melanoma:many ar- rows in the quiver[J]. J Surg Oncol, 2014, 109(4):295. doi: 10.1002/jso.23559
[12]	Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Ad- vanced Melanoma[J]. J Clin Oncol, 2015, 33(25):2780-2788. doi: 10.1200/JCO.2014.58.3377
[13]	Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KN- 001[J]. Ann Oncol. 2019 31. doi: 10.1093/annonc/mdz011.
[14]	Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced- dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.[J]. Lancet Oncol, 2017, 18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X
[15]	Wang D, Jiang W, Zhu F, et al. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy[J]. Int J Oncol, 2018, 53(3):1193- 1203. http://cn.bing.com/academic/profile?id=946ce0567b647f7cb8758006dbc40ad4&encoded=0&v=paper_preview&mkt=zh-cn
[16]	Bradish JR, Montironi R, Lopez- Beltran A, et al. Towards personal- ized therapy for patients with malignant melanoma: molecular in- sights into the biology of BRAF mutations[J]. Future Oncol, 2013, 9 (2):245- 253. doi: 10.2217/fon.12.179
[17]	Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced braf(v600)-mutant melanoma(co- brim): updated efficacy results from a randomised, double blind, phase 3 trial [J]. LaIlcet 0ncol, 2016, 17(9):1248-1260. https://www.ncbi.nlm.nih.gov/pubmed/27480103/
[18]	Larkin JPA, Dreno B, et al. Combined vemurafenib and cobimetinib in braf -mutated melanoma[J]. N Engl J Med, 2014, 371(20):1867- 1876. doi: 10.1056/NEJMoa1408868
[19]	Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double- blind, phase 3 trial [J]. Lancet Oncol, 2016, 17(9):1248-1260. doi: 10.1016/S1470-2045(16)30122-X
[20]	Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2
[21]	Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chi- nese melanoma patients:Large scale analysis of BRAF and NRAS mutations in a 432- case cohort[J]. Eur J Cancer, 2012, 48(1):94- 100. doi: 10.1016/j.ejca.2011.06.056
[22]	Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600 - mutant advanced melanoma treated with vemurafenib[J]. N Eng J Med, 2012, 366(8):707-714. doi: 10.1056/NEJMoa1112302
[23]	Lian B, Si L, Cui C, et al. Phase Ⅱ randomized trial comparing high- dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.[J]. Clin. Cancer Res, 2013, 19(16): 4488-4498. doi: 10.1158/1078-0432.CCR-13-0739
[24]	Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006[J].Br J Cancer, 2018, 119(6):670-674. doi: 10.1038/s41416-018-0207-6
[25]	Tang B, Yan X, Sheng X, et al. Safety and clinical activity with an anti-PD- 1 antibody JS001 in advanced melanoma or urologic cancer patients. [J].J Hematol Oncol, 2019, 12(1):7. doi: 10.1186/s13045-018-0693-2
[26]	Kong Y, Sheng X, Wu X, et al. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/ 6 Inhibitors in Targeted Therapy.[J].Clin. Cancer Res., 2017, 23(22):6946- 6957. doi: 10.1158/1078-0432.CCR-17-0070